Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Baricitinib vid behandling av tarmbehçets syndrom

17 september 2026 uppdaterad av: Peking Union Medical College Hospital

En multicenter, prospektiv, öppen etikett, randomiserad studie för att utforska effektivitet och säkerhet för baricitinib i eldfast tarmbehçets syndrompatienter

This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS). The objective is to demonstrate if Baricitinib is non-inferior to ADA in controlling BS inflammation, reducing BS recurrence, alleviating gastrointestinal symptoms and promoting intestinal mucosal healing.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

The non-inferiority will be established by comparing the lower bound of the two-sided 95% confidence interval with the non-inferiority margin. If the lower bound was larger than the margin, Baricitinib would be regarded as non-inferiror to ADA. Superority will be further assessed in case that the non-inferiority is established. Both ITT and PP analysis will be conducted for the primary outcome given the non-inferiority design. Trial result will be primarily interpreted based on ITT analysis.

Studietyp

Interventionell

Inskrivning (Beräknad)

56

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Wenjie Zheng, M.D.

Studera Kontakt Backup

Studieorter

      • Beijing, Kina
        • Rekrytering
        • Peking Union Medical College Hospital
        • Kontakt:
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100730
        • Har inte rekryterat ännu
        • Peking Union Medical College Hospital
        • Kontakt:
          • Wenjie Zheng, M.D.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Refer to the consensus on the diagnosis and treatment of intestinal Behçet's syndrome in China: Patients who meet the 2013 International Criteria for Behçet's Disease (ICBD) and have typical Behçet's syndrome-related intestinal ulcers confirmed by colonoscopy, or patients diagnosed according to the criteria for Behçet's syndrome established by the Korean Behçet's Disease Collaborative Group in 2009;
  2. Patients have a DAIBD score ≥ 40 points or intestinal symptom score ≥ 3 points at baseline;
  3. Endoscopic examination conducted within 60 days before inclusion suggests active intestinal ulcers;
  4. Patients who have been treated with medium to high-dose steroids (prednisolone equivalent of 0.5-1 mg/kg/day) for more than 1 month continuously, or any immunomodulator/Immunosuppressants for more than 3 months regularly or biologics for more than 2 months, as judged by the doctor to be treatment failure or intolerance;
  5. Currently steroid dose ≤ 30 mg prednisolone equivalent, stabilized for ≥ 2 weeks, and/or stabilized immunomodulator dose for ≥ 4 weeks;
  6. Understanding the research process, voluntary participation, and signing of informed consent.

Exclusion Criteria:

  1. Diagnosis of other diseases such as Crohn's disease, ulcerative colitis, lymphoma, etc.;
  2. Other active organ damage related to BS requires intensified immunosuppressive therapy, including aneurysms, uveitis, and substantial involvement of the central nervous system; skin lesions and joint involvement can be included;
  3. Severe organ dysfunction including ALT, AST, TBIL levels exceeding twice the upper limit of normal, creatinine levels exceeding 1.5 times the upper limit of normal, white blood cell count < 3×10^9/L, ANC < 2×10^9/L, hemoglobin < 80g/L, platelets < 100×10^9/L;
  4. Active infections such as active tuberculosis, active hepatitis B or C, syphilis, chronic Epstein-Barr virus infection, HIV infection, sustained or severe bacterial or viral infections, and history of severe herpes zoster;
  5. Patients with latent tuberculosis must undergo ≥3 weeks of prophylactic anti-tuberculosis treatment before inclusion;
  6. Primary immunodeficiency disease;
  7. History of cancer, or endoscopic intestinal histopathology indicating intraepithelial neoplasia or malignancy, or presence of other malignancies;
  8. Patients who did not respond to infliximab treatment for primary refractory BS (patients with secondary failure, intolerance, or allergy to infliximab should be included);
  9. Patients treated with biologics/small molecule targeting therapies within 5 half-lives (including use of tofacitinib within 10 days, etanercept within 4 weeks, infliximab within 8 weeks, golimumab, certolizumab, abatacept, and tocilizumab within 10 weeks, ustekinumab within 6 months);
  10. Patients with prior use of baricitinib or ADA;
  11. Complications of intestinal BS such as symptomatic stenosis, short bowel syndrome, intestinal fistula, or suspected intra-abdominal abscess; potential need for surgery or situations not conducive to DAIBD and efficacy assessment; any form of intestinal resection or other abdominal surgery within 6 months before baseline; presence of a functioning (i.e., patent) stoma or ostomy;
  12. Patients requiring parenteral nutrition due to disease severity;
  13. Pregnant, lactating, or planning pregnancy soon;
  14. Patients unwilling or unable to comply with regular visits;
  15. History of severe thrombotic events or chronic cardiovascular events.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Baricitinib för ibs

Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with Baricitinib 4 mg/day for 6 months.

Andra namn:
  • Olumiant®
Experimentell: Adalimumab för IBS

Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with ADA (initially ADA 160 mg subcutaneous injection, followed by 80 mg ADA after 2 weeks, then 40 mg ADA every 2 weeks thereafter) for 6 months.

Andra namn:
  • Humira®

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of patients with marked improvement (MI) at week 24 of follow-up
Tidsram: Baseline to week 24

Based on the combined assessment of gastrointestinal symptoms and endoscopy scores[1], gastrointestinal symptom scoring is defined as follows: 0 points, asymptomatic; 1 point, does not affect daily life; 2 points, mildly affects daily life; 3 points, moderately affects daily life; 4 points, severely affects daily life. Endoscopy scoring is defined as follows: 0 points, mucosal healing; 1 point, maximum ulcer ≤ original 1/4; 2 points, maximum ulcer between original 1/4 and 1/2; 3 points, maximum ulcer ≥ original 1/2 or enlargement. Marked improvement is defined as gastrointestinal symptom and endoscopy scores both ≤ 1.

[1]Sugimura, N. et al. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease. Dig. Liver Dis. 51, 967-971 (2019).

Baseline to week 24

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Andel patienter med förbättring av ≥1 poäng i gastrointestinala symptomresultat jämfört med baslinjen vid vecka 24 av uppföljningen
Tidsram: Baslinje till vecka 24
Baslinje till vecka 24
Proportion of patients with CR (complete response) at week 24 of follow-up
Tidsram: Baseline to week 24

CR is defined as both gastrointestinal symptoms and endoscopy scores being 0.

Baseline to week 24
Changes in C-reactive protein (CRP) compared to baseline
Tidsram: Baseline to week 24

The hs-CRP is acute phase reactants that are indicative of the patient's disease activity.

Baseline to week 24
Changes in erythrocyte sedimentation rate (ESR) compared to baseline
Tidsram: Baseline to week 24

The ESR is acute phase reactants that are indicative of the patient's disease activity.

Baseline to week 24
Changes in DAIBD scores compared to baseline
Tidsram: Baseline to week 24

Disease Activity Index for Intestinal Behcet's Disease (DAIBD);

Baseline to week 24
Changes in BDCAF scores compared to baseline
Tidsram: Baseline to week 24

Behçet's Disease Current Activity Index (BDCAF);

Baseline to week 24
Changes in SF-36 of life questionnaires compared to baseline
Tidsram: Baseline to week 24

Short Form (36) Health Survey(SF-36);

Baseline to week 24
Changes in IBDQ quality of life questionnaires compared to baseline
Tidsram: Baseline to week 24

Inflammatory Bowel Disease Questionnaire (IBDQ)

Baseline to week 24
Incidence of Treatment-Emergent Adverse Events
Tidsram: Baseline to week 24

Record the types, frequency, and severity of adverse events, as well as the number of study participants who were drop out due to any adverse events. Adverse event: Any medical condition that affects the health of the participant during the study or worsens a preexisting medical condition, regardless of whether it is causally related to the study, is considered an adverse event.

This can be symptoms, signs, or abnormal laboratory tests. Serious adverse event (SAE): Any significant medical event that causes death, is life-threatening, requires hospitalization, results in permanent or severe disability or loss of function, or the investigator deems it a significant medical event that may seriously harm the participant or require medical intervention to prevent the above outcomes.

The causal relationship between the serious adverse event and the study is determined by the investigator's discussion.

Baseline to week 24

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

8 november 2024

Primärt slutförande (Beräknad)

30 juni 2027

Avslutad studie (Beräknad)

30 juni 2028

Studieregistreringsdatum

Först inskickad

31 juli 2024

Först inskickad som uppfyllde QC-kriterierna

23 februari 2025

Första postat (Faktisk)

27 februari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera